TI presents first double-blind data supporting phenytoin 10% cream in painful polyneuropathies at FIGON Dutch Medicines Days

TI presents first double-blind data supporting phenytoin 10% cream in painful polyneuropathies at FIGON Dutch Medicines Days Every year FIGON (Federatie Innovatie Geneesmiddel Onderzoek Nederland: Dutch Federation Innovative Medicine Research) is organizing a 2-day conference. On the 23rd of September 2019 at  the FIGON Dutch Medicines Days David Kopsky on behalf of TI has presented…

Topical Innovation’s strategy supported: focus on broad-acting sodium channel blocker has higher likelihood of success

Topical Innovation’s strategy supported: focus on broad-acting sodium channel blocker has higher likelihood of success Nature’s review of April 8, 2019 is a further supportive piece of evidence for Topical Innovation’s strategy of developing a broad-acting sodium channel blocker as a topical treatment for neuropathic pain. Author Kingwell points out that despite compelling genetic validation,…

New Paradigm makes use of placebo controlled tests in daily practice: an innovation

New Paradigm makes use of placebo controlled tests in daily practice: an innovation The physicians of topical innovations have developed at their center in the Netherlands, patients a new placebo controlled test paradigm. In order to identify putative responders and exclude an (initial) placebo-response, first a single-blind and subsequently a double-blind placebo-controlled response tests has…

Topical Treatment of painful chemotherapy-induced neuropathy: new evidence

Topical Treatment of painful chemotherapy-induced neuropathy: new evidence Julien Rossignol et al. (2019) from Inserm and University Paris Descartes, Paris, France published a paper on the effects of high dose topical amitriptyline in painful chemotherapy-induced neuropathy: 10%. We advocated such high dose already years ago based on our clinical data. (Kopsky DJ, Hesselink JM (2012)…